Opterion Health Hires Additional Management Personnel

Mylène Fleurant, Peter Reinemer, Daniel Lustenberger, and Ulrike Grimm join Opterion’s management team.

FREMONT, CA: Opterion Health AG, a nephrology firm focused on PD innovation, strengthens its executive team, including Daniel Lustenberger as Chief Financial Officer (CFO) and Peter Reinemer as Chief Technology Officer (CTO). Mylène Fleurant has been named Director of Quality, and Ulrike Grimm has been named Director of Project Management. Andreas Schmidt, who will succeed Daniel Lustenberger as CFO, will remain a partner at Opterion Health.

Daniel Lustenberger, CFO

Daniel Lustenberger is an accomplished international finance, accounting, and management consulting executive who will join Opterion Health as Chief Financial Officer in September 2021. He is a certified public accountant in Switzerland, holds an Executive MBA from IMD in Lausanne, and has over 20 years of life sciences and technology expertise.

Peter Reinemer, Chief Technology Officer

Peter Reinemer has worked in the pharmaceutical and biotechnology industries for 30 years. He began his career with Bayer Pharma, where he worked in discovery research for nearly a decade in Germany and Japan.

Mylène Fleurant, Head of Quality

Mylène Fleurant spent over two decades in the life sciences business, heading for quality assurance (QA). She spent ten years at Novartis as Region Head Quality Europe and at Merck Serono implementing global quality systems. Before establishing her consulting firm in 2019, Mylène worked as Global Head of Quality Assurance at Novimmune and as Vice President of Quality Affairs at Alvotech.

Ulrike Grimm, Head of Project Management

Opterion Health hired Ulrike Grimm in June 2020 to build project excellence for the company’s development program. Ulrike began her career as a sales representative for Sanol Pharma before joining Merck KGaA in 1997. 

She held increasing levels of responsibility, beginning as team leader for research and development projects and progressing to product leader for Merck’s second commercial oncology medicine.

Björn Englund, CEO of Opterion Health, comments, “Opterion Health is at a critical phase in its growth strategy, and these key appointments will help us to accelerate the commercialization of our innovative PD solution, which is designed to decrease metabolic challenges, particularly for the estimated 45 percent of dialysis patients who also suffer from diabetes but also for the non-diabetic patients.”

 David Ebsworth, Chairman of Opterion Health, says, “I am grateful to Andreas Schmidt for his outstanding contribution to the success of Opterion Health, which is now well-financed and on track to establish a new standard in peritoneal dialysis. As we strive to complete preclinical work and to enter Phase 1 studies, it is essential to have the best possible team in place and I am delighted to welcome Daniel, Mylène, Peter and Ulrike. Their specialist experience and expertise will greatly assist Opterion Health in achieving its goal of bringing much-needed innovation to dialysis patients, improving their quality of life and enabling them to manage the treatment in their own home.”

Opterion Health is creating the first substantial advance in Parkinson’s disease in over two decades, intending to increase patients’ quality of life and independence. The invention will keep the Peritoneum in place for a more extended amount lowering the danger of hospitalization and scantly reducing dialysis-related healthcare expenses. Earlier this year, the company closed a bridge financing round and opened new premises in Muttenz, Baselland. Opterion Health has appointed Björn Englund, a renowned expert in dialysis, as CEO to assist in preparing for the start of clinical studies in the next one to two years.